Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Cortex Pharmaceuticals Articles

Cortex and Pier Pharma in all-share merger

15 August 2012

Servier links with Miragen for cardiovascular drugs; takes up Ampakine option

20 October 2011

Cortex could gain $3 million in Ampakine deal with Lab Servier

15 June 2011

Cortex reacquires all Ampakine compounds, IP and rights from Valeant; cuts loss

22 March 2011

Merck & Co returns Ampakine compounds rights to Cortex; signs antibacterials deal with BioRelix

5 October 2010

Cortex sells selected Ampakine compounds and rights to respiratory depression indication to Biovail for up to $25 million

29 March 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS